{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:20:26Z","timestamp":1790698826769,"version":"4.1.0"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":2556,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,9]]},"DOI":"10.1111\/j.1365-2230.2008.02976.x","type":"journal-article","created":{"date-parts":[[2008,8,14]],"date-time":"2008-08-14T11:49:40Z","timestamp":1218714580000},"page":"551-554","source":"Crossref","is-referenced-by-count":53,"title":["Methotrexate for psoriasis in the era of biological therapy"],"prefix":"10.1093","volume":"33","author":[{"given":"R. B.","family":"Warren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. J. G.","family":"Chalmers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. E. M.","family":"Griffiths","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Menter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","reference":[{"key":"10.1111\/j.1365-2230.2008.02976.x-BIB1","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1111\/j.1365-2133.1986.tb05780.x","article-title":"Methotrexate for intractable benign familial chronic pemphigus","volume":"115","author":"Fairris","year":"1986","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1365-2230.2008.02976.x-BIB2","doi-asserted-by":"crossref","first-page":"182","DOI":"10.7326\/0003-4819-81-2-182","article-title":"Polymyositis and dermatomyositis: combined methotrexate and corticosteroid therapy","volume":"81","author":"Metzger","year":"1974","journal-title":"Ann Intern Med"},{"key":"10.1111\/j.1365-2230.2008.02976.x-BIB3","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/j.1365-2133.1977.tb15068.x","article-title":"Cutaneous sarcoidosis treated with methotrexate","volume":"97","author":"Veien","year":"1977","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1365-2230.2008.02976.x-BIB4","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1097\/00000441-195102000-00009","article-title":"Therapeutic suppression of tissue reactivity. II. Effect of aminopterin in rheumatoid arthritis and psoriasis","volume":"221","author":"Gubner","year":"1951","journal-title":"Am J Med Sci"},{"key":"10.1111\/j.1365-2230.2008.02976.x-BIB5","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/j.1365-2133.2007.08315.x","article-title":"Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION)","volume":"158","author":"Saurat","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1365-2230.2008.02976.x-BIB6","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1046\/j.1365-2230.2000.00638.x","article-title":"The use of folic acid supplementation in psoriasis patients receiving methotrexate: a survey in the United Kingdom","volume":"25","author":"Kirby","year":"2000","journal-title":"Clin Exp Dermatol"},{"key":"10.1111\/j.1365-2230.2008.02976.x-BIB7","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1111\/j.1365-2133.2006.07289.x","article-title":"Folic acid supplementation during treatment of psoriasis with methotrexate: a randomized, double-blind, placebo-controlled trial","volume":"154","author":"Salim","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1365-2230.2008.02976.x-BIB8","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/art.23144","article-title":"Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial","volume":"58","author":"Braun","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1111\/j.1365-2230.2008.02976.x-BIB9","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/S0190-9622(98)70508-0","article-title":"Methotrexate in psoriasis: consensus conference","volume":"38","author":"Roenigk","year":"1998","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1365-2230.2008.02976.x-BIB10","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/j.1365-2133.2005.06605.x","article-title":"Noninvasive monitoring for methotrexate hepatotoxicity","volume":"152","author":"MacDonald","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1365-2230.2008.02976.x-BIB11","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/j.1365-2133.2005.06422.x","article-title":"Replacement of routine liver biopsy by procollagen III aminopeptide for monitoring patients with psoriasis receiving long-term methotrexate: a multicentre audit and health economic analysis","volume":"152","author":"Chalmers","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1365-2230.2008.02976.x-BIB12","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/j.1365-2133.1994.tb02901.x","article-title":"Methotrexate revisited: effects of long-term treatment in psoriasis","volume":"130","author":"Van Dooren-Greebe","year":"1994","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1365-2230.2008.02976.x-BIB13","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1046\/j.1468-3083.2000.00058.x","article-title":"Methotrexate in psoriasis: 26\u2003years experience with low-dose long-term treatment","volume":"14","author":"Haustein","year":"2000","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1111\/j.1365-2230.2008.02976.x-BIB14","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1186\/ar419","article-title":"Molecular action of methotrexate in inflammatory diseases","volume":"4","author":"Chan","year":"2002","journal-title":"Arthritis Res"},{"key":"10.1111\/j.1365-2230.2008.02976.x-BIB15","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S0140-6736(05)67566-6","article-title":"Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial","volume":"366","author":"Reich","year":"2005","journal-title":"Lancet"},{"key":"10.1111\/j.1365-2230.2008.02976.x-BIB16","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/S0140-6736(08)60726-6","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)","volume":"371","author":"Papp","year":"2008","journal-title":"Lancet"},{"key":"10.1111\/j.1365-2230.2008.02976.x-BIB17","first-page":"116","article-title":"Methotrexate vs. ciclosporin in psoriasis: effectiveness, quality of life and safety. A randomized controlled trial","volume":"158","author":"Flytstrom","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1365-2230.2008.02976.x-BIB18","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1056\/NEJMoa021359","article-title":"Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis","volume":"349","author":"Heydendael","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1365-2230.2008.02976.x-BIB19","doi-asserted-by":"crossref","first-page":"194","DOI":"10.2165\/00003088-199630030-00002","article-title":"Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis","volume":"30","author":"Bannwarth","year":"1996","journal-title":"Clin Pharmacokinet"},{"key":"10.1111\/j.1365-2230.2008.02976.x-BIB20","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/978-1-4615-2584-4_89","article-title":"The antiinflammatory effects of methotrexate are mediated by adenosine","volume":"370","author":"Cronstein","year":"1994","journal-title":"Adv Exp Med"},{"key":"10.1111\/j.1365-2230.2008.02976.x-BIB21","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1468-3083.2007.02264.x","article-title":"A pilot study of pharmacokinetically guided dosing of oral methotrexate in the initial phase of psoriasis treatment","volume":"22","author":"Hroch","year":"2008","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1111\/j.1365-2230.2008.02976.x-BIB22","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1373\/49.10.1632","article-title":"HPLC determination of erythrocyte methotrexate polyglutamates after low-dose methotrexate therapy in patients with rheumatoid arthritis","volume":"49","author":"Dervieux","year":"2003","journal-title":"Clin Chem"},{"key":"10.1111\/j.1365-2230.2008.02976.x-BIB23","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1159\/000250839","article-title":"Severe psoriasis - oral therapy with a new retinoid","volume":"157","author":"Fredriksson","year":"1978","journal-title":"Dermatologica"},{"key":"10.1111\/j.1365-2230.2008.02976.x-BIB24","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/978-3-642-94744-5_2","article-title":"Moderne problem der humangenetik","volume":"12","author":"Vogel","year":"1959","journal-title":"Ergeb Inn Med Kinderheilkd"},{"key":"10.1111\/j.1365-2230.2008.02976.x-BIB25","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1038\/sj.jid.5700808","article-title":"Polymorphisms in folate, pyrimidine, and purine metabolism are associated with efficacy and toxicity of methotrexate in psoriasis","volume":"127","author":"Campalani","year":"2007","journal-title":"J Invest Dermatol"},{"key":"10.1111\/j.1365-2230.2008.02976.x-BIB26","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1038\/jid.2008.16","article-title":"Genetic variation in efflux transporters influences outcome to methotrexate therapy in patients with psoriasis","volume":"128","author":"Warren","year":"2008","journal-title":"J Invest Dermatol"},{"issue":"Suppl. 1","key":"10.1111\/j.1365-2230.2008.02976.x-BIB27","first-page":"2","article-title":"Genetic variation across the methotrexate metabolic pathway and its influence upon treatment outcomes in patients with psoriasis","volume":"157","author":"Warren","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1365-2230.2008.02976.x-BIB28","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1111\/j.1365-2133.2005.06880.x","article-title":"The potential of pharmacogenetics in optimizing the use of methotrexate for psoriasis","volume":"153","author":"Warren","year":"2005","journal-title":"Br J Dermatol"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2230.2008.02976.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1365-2230.2008.02976.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T09:28:42Z","timestamp":1709198922000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/33\/5\/551\/6625563"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,9]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008,9]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2230.2008.02976.x","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,9]]}}}